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Background: Diabetic peripheral neuropathy (DPN) is a common, symptomatic, long-term complication of diabetes
mellitus. Many of the agents used to treat DN have not been compared with each other. This study was, therefore,
undertaken to compare the efficacy and safety of carbamazepine, pregabalin and alpha-lipoic acid in diabetic
neuropathy patients.
Methods: This was a prospective, observational study. The patients were categorized into three groups, Group I
included those patients who were prescribed carbamazepine while group II included those on pregabalin and
group III patients received alpha-lipoic acid. Each patient was followed up at every month for total duration of
6 months. Demographic details, presenting symptoms, history of diabetes, laboratory values pertaining to diabetes
(Fasting blood sugar, Post prandial blood sugar and HbA1c) were recorded. Intensity of pain, using a visual
analogue scale (VAS), diabetic neuropathy symptom (DNS) score and diabetic neuropathy examination (DNE) score
were assessed at baseline and then at each monthly follow-up. Nerve conduction velocity (NCV) was also measured
at baseline and then at the end of 3 and 6 months.
Results: A total of 101 patients were enrolled out of them 96 completed the study. Regarding VAS, the number of
patients having pain was reduced substantially however, the speed and the quantum of this reduction were best in
group II (pregabalin). Regarding DNS, also group II showed the best response in terms of number of patients as
well as the speed of improvement. The results also imply that the relief from diabetic neuropathy (as per DNE
score) is superior with pregabalin administration. However, no improvement in NCV was evident in any group.
Conclusion: Results of this study suggest that treatment with pregabalin gives faster and better improvement in
diabetic neuropathy.
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Diabetic peripheral neuropathy (DPN) is a common,
symptomatic, long-term complication of type 1 and 2
diabetes mellitus. At the initial diagnosis, 10% of the pa-
tients already experience pain, and about 50% are afflicted
with this complication after 25 years of the disease [1].
Neuropathies are characterized by a progressive loss of
nerve fibers, which may affect both the somatic as well as
autonomic nervous system. The clinical features vary im-
mensely, and patients may present a variety of complaints* Correspondence: neeralpatel@ymail.com
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unless otherwise stated.ranging from paraesthesias to disabling neuropathy and
cardiac arrhythmias. Mechanisms involved behind nerve
damage are persistent hyperglycemia, microvascular in-
sufficiency, oxidative and nitrosative stress, defective
neurotrophism, and autoimmune nerve destruction. DN
is the leading cause of diabetes-related hospital admis-
sions and non-traumatic amputations [2,3]. It leads to a
major physical disability, poor quality of life [4], high
mortality [3], and an estimated total annual cost of $22
billion [5].
A large number of randomized clinical trials have been
conducted to assess the efficacy of various therapeutic
agents but the results have been disappointing, mostd. This is an Open Access article distributed under the terms of the Creative
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in its pathogenesis [3,6]. Therefore, till date no effective
treatment exists for DN, other than the control of hyper-
glycemia [7,8]. Several drugs have been used with varying
degree of success including antidepressants (primarily tri-
cyclic antidepressants or TCAs) and anti-epileptics (car-
bamazepine, gabapentin, pregabalin, lamotrigine, sodium
valporate and topiramate). Other drugs like α-lipoic acid,
baclofen, levodopa, methcobalamin, bupropion, are also
claimed to be beneficial. Many of the agents used to treat
DN have not been compared with each other. Also, the
end points in many of the studies have varied, making
it difficult to compare the treatments [9]. This study
therefore aimed to compare the efficacy and safety of
carbamazepine (older treatment), pregabalin (currently
preferred) and alpha lipoic acid (newer drug) in the
treatment of diabetic neuropathy.
Materials and methods
This was a prospective, observational study conducted at
the Diabetic outpatient department, of a tertiary care,
teaching hospital. The study was carried out over a period
of 21 months from October 2010 to June 2012. Approval
from The Institutional Ethics Committee (Institutional
Ethics Committee, BJMC, Ahmedabad) was obtained. The
enrolled patients were followed up monthly for 6 months.
They were categorized into three groups according to
treatment prescribed by the physician. Group I included
those patients of diabetic neuropathy (DN) who were pre-
scribed carbamazepine while group II included those on
pregabalin and group III patients received alpha-lipoic
acid. Demographic details, presenting symptoms, history
of diabetes, laboratory values pertaining to diabetes (FBS,
PPBS and HbA1c) were recorded. Several tests were con-
ducted to assess the severity of DN and its amelioration in
response to the treatment given. Intensity of pain, using a
visual analogue scale (VAS), diabetic neuropathy symptom
score (DNS) and diabetic neuropathy examination score
(DNE) were assessed at baseline and then at each monthly
follow-up. Nerve conduction velocity (NCV) was mea-
sured at baseline and then at the end of 3 and 6 months.
The VAS used for measuring the pain intensity was a
10-cm horizontal line that ranged from no pain (0) to
worst pain (10) imaginable with mild, moderate, severe
and very severe grades [10]. DNS consists of four ques-
tions related to symptoms of diabetic neuropathy. At
every visit, patients were asked if they had experienced
any of these symptoms during the last two weeks. For
each question a positive reply was counted as one point
and negative as zero. If total score (out of 4) was one or
more, diabetic neuropathy was considered to be present
[11]. DNE score (diabetic neuropathy examination score)
consists of eight parameters including two for muscle
strength, one for tendon reflex and five for sensations. Atotal score (out of 16) was recorded for each patient and
those having it > 3 were diagnosed to be suffering from
diabetic neuropathy [12]. NCV (nerve conduction velocity)
was evaluated on both tibial and peroneal nerves on both
the legs.
Data analysis
The value of each test was compared with baseline and
between groups using Fisher’s exact test andone way
analysis of variance (ANOVA). Adverse drug reactions
were recorded and analysed.
Results
A total of 101 patients were enrolled for the study. Out
of them 96 completed the study (44 male and 52 female)
whereas 5 patients were lost to follow up due to non
compliance. The mean age of patients in group I (carba-
mazepine) was 54.5 ± 8.3 years, 54.8 ± 7.2 years in group
II (pregabalin) and 57.3 ± 8 years in group III (alpha-
lipoic acid). The average duration of diabetes was 10.43 ±
3.42 years (no statistical difference between groups). There
were 51 patients taking oral hypoglycemic drugs, 12 pa-
tients received insulin while 33 patients were receiving
both. Hypertension was the most common concomitant
disease (n = 47). At baseline, the most common symptom
of diabetes was polyuria (78.8, 84.3 and 70.9% patients in
group I, II and III respectively) followed by polydypsia
(45.4, 34.3 and 45.2% patients in group I, II and III, re-
spectively). A significant (p < 0.05) reduction in number
of patients having polyuria (57.7, 77.7 and 59.1%in
Group I, II and II respectively) and polydypsia (93.3,
72.7 and 78.6% in Group I, II and III respectively) was
observed in each group at the end of the study. At base-
line the most common presenting symptom of diabetic
neuropathy (DN) was burning/aching pain in one or
both lower limbs reported by all patients. Pricking sen-
sation in one or both lower limbs was the next common
symptom reported by majority of the patients in all
three groups (72.8% in group I, 81.3 in group II and 71%
in group III). Improvement in symptoms of DN was no-
ticeable in all three groups but it was relatively faster
and better in patients of group II (pregabalin) starting
from first follow up itself. In all the groups, a significant
(p < 0.05) improvement in FBS, PPBS and HbA1c was
also seen in with effect from first or second follow up
and was maintained until the end of study.
Pain
Severity of pain (as assessed by VAS) was classified into
six categories, 0 = no pain, 1–2 =mild, 3–4 =moderate, 5–
6 = severe, 7–8 = very severe and 9–10 = worst pain. A de-
tailed classification of patients in each category is given in
Table 1. At baseline, no patient was classified as ‘no pain’
or ‘worst pain’ in all three groups. A significant (p < 0.05)
Table 1 Distribution of patients suffering from neuropathic pain
Severity of pain
(as per VAS score)#
Number of patients
Baseline 1st FU 2nd FU 3rd FU 4th FU 5th FU 6th FU
Group I (n=33) (Carbamazepine) No pain (0) 0 3 5 12** 22** 27** 28**
Mild pain (1–2) 6 8 12 10 8 4 4
Moderate pain (3–4) 14 14 12 8 2** 2** 1**
Severe pain (5–6) 8 4 3 2 1* 0** 0**
Very severe pain (7–8) 5 4 1 1 0 0 0
Group II (n=32) (Pregabalin) No pain (0) 0 8** 13** 18** 27** 30** 32**
Mild pain (1–2) 6 8 11 12 4 2 0
Moderate pain (3–4) 22 15 8** 2** 1** 0** 0**
Severe pain (5–6) 3 1 0 0 0 0 0
Very severe pain (7–8) 1 0 0 0 0 0 0
Group III (n=31) (Alpha lipoic acid) No pain (0) 0 5 8* 14** 23** 25** 29**
Mild pain (1–2) 8 14 14 11 6 5 2
Moderate pain (3–4) 16 10 9 6* 2** 1** 0**
Severe pain (5–6) 5 1 0 0 0 0 0
Very severe pain (7–8) 2 1 0 0 0 0 0
FU= Follow-Up, *p<0.05, **p < 0.01 as compared to baseline (Fisher’s exact test), #no patient was classified as ‘worst pain (9–10)’ in any group at any time,
VAS= visual analogue scale.
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up in group I, 1st follow up in group II and 2nd follow up
in group III. A further analysis of patients having ‘no pain’
revealed that group II had significantly (p < 0.05) higher rate
of improvement as compared to other groups up to fourth
follow up, while there was no significant difference between
groups I and III. It is apparent that while the number of
patients having mild, moderate, severe and very severe
pain was reduced substantially by the end of the study (as
compared to baseline), the speed and the quantum of this
reduction was best in group II (pregabalin).Figure 1 Number of symptom free patients as per diabetic neuropathSymptomatic improvement
The number of patients in each group with the zero
DNS score (depicting total freedom from the symptoms
of diabetic neuropathy) was also calculated at every follow
up. An approximately similar number of patients were ob-
served to be having zero score by the end of this study.
However, group II showed the best response in terms of
number of patients as well as the speed of improvement
as compared to group I and III. The difference in improve-
ment between group II and group I and III was statistically
significant (p < 0.05) (Figure 1).y symptom (DNS) score.
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DNE score less than three is considered as absence of dia-
betic neuropathy. At every follow up number of patients
having DNE score less than three was noted. A significant
(p < 0.05) improvement was evident only in group II at
fifth and sixth follow ups (6 and 8 patients out of 32 re-
spectively). It was observed that the number of patients
with absence of DN (score less than 3) was significantly
more in group II than group I and III. The difference
noted between group I and III was statistically insignifi-
cant (Figure 2). The results imply that the relief from dia-
betic neuropathy (as per DNE score) is superior with
pregabalin administration as compared to carbamazepine
and alpha lipoic acid.
Nerve conduction velocity
No improvement in NCV was evident in any group at
3rd or 6th follow ups. These results showed that there
was no change in basic pathophysiology of diabetic neur-
opathy in any of the treatment group.
Correlation between glycemic control and diabetic
neuropathy
A correlation between glycemic control (as assessed by
FBS) and parameters of DN (VAS, DNS and DNE) was
studied. Only group I showed a significant (p < 0.05) cor-
relation between FBS and VAS (correlation coefficient (r)
was 0.35, confidence interval (95%) 0.01 to 0.6 and coeffi-
cient of determination (r [2]) 0.12). This means that the
improvement in FBS correlates with improvement in VAS
in patients treated with carbamazepine (Figure 3).
Regarding safety, the drug therapy was well tolerated
in all groups. Only three (3) adverse drug reactions were
reported during the study period. Two patients developed
rashes with carbamazepine while one had somnolence
with pregabalin. These ADRs were non-serious in nature
and the patients recovered completely.
Discussion
Diabetic neuropathy is a common long term complication
of diabetes mellitus affecting nearly 50% of the patientsFigure 2 Number of patients with less than free score on diabetic ne[13]. The mean age of the patients in our study (n = 96)
was 55.28 ± 7.85 years which is similar to other studies
[14-16]. It is reported that the advancing age increases the
incidence of neuropathy. The average duration of diabetes
in our study was 10 years which is not very long yet corre-
lates well with previous reports [16,17]. Prolonged expos-
ure of peripheral nerves to hyperglycemia in long standing
diabetics predisposes them to development of neuropathy.
The role of glycemic control in development as well as
progression of DN is supported by the available evidence
[18]. In our study, the most common presenting symptom
of DN was burning/aching pain in one or both lower
limbs. Pricking sensation was the next common symptom
followed by unsteadiness on walking and numbness in that
order. A significant (p < 0.05) improvement in burning/
aching pain and pricking sensation was found in all the
treatment groups at various follow ups. However, patients
treated with pregabalin showed the best response in terms
of rate (100%) and speed of improvement. While a similar
results for early and sustained improvement with pregaba-
lin have been reported [19], a meta-analysis of seven ran-
domized trials has also described the similar findings [20].
We conducted several specialized tests to evaluate the
status of pain (visual analogue scale), other symptoms
(diabetic neuropathy symptom score) and signs (diabetic
neuropathy examination) of diabetic neuropathy as well
as the peripheral nerve physiology (nerve conduction
velocity). As known, pain and sensation abnormality are
the classical symptoms of DN. We evaluated them by
using visual analogue scale (VAS) and neuropathy symp-
toms score (DNS) respectively. VAS is a reliable, valid and
widely used test to assess the pain intensity. According to
VAS score six categories can be classified ranging from no
pain (0) to worst possible pain (9–10) [21]. Our results
using VAS confirmed the clinical observations about pain
in DN described above. Complete relief from pain (‘no
pain’) should be considered to be more important than a
simple reduction in pain intensity over long term. We
found that the number of patients in ‘no pain’ category at
every follow up increased significantly (p < 0.05) in all the
groups. However, the reduction in mean VAS scores anduropathy examination (‘no neuropathy’).
Figure 3 Correlation betweeen fasting blood sugar and degree of pain in patients suffering from neurophy treated with carbamazepine.
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with pregabalin. It is difficult to explain a superior re-
sponse to pregabalin. It, however, appears that a unique
mechanism action of pregabalin may be responsible for
this. Pregabalin blocks alpha 2 delta protein, an auxillary
subunit of voltage gated calcium channel. It also reduces
the synaptic release of several neurotransmitters appar-
ently by the same mechanism which possibly results in the
reduction of neuronal excitability and ultimately the pain
[22]. On the other hand, the diabetic neuropathy symptom
score is also a validated and widely accepted scoring sys-
tem for screening of diabetic neuropathy [23]. It comprises
four questions in relation to the symptoms of diabetic
neuropathy. It is calculated on the basis of total positive
replies. DNS greater than one is considered as presence of
diabetic peripheral neuropathy. This score is also valid to
be used for predictive purpose or prognostics [11]. Num-
ber of patients achieving zero score (no symptoms) were
similar with pegabalin and alpha lipoic acid (78 vs 74%).
Our results imply that although pregabalin shows a faster
rate of improvement, it is otherwise therapeutically
equivalent to alpha lipoic acid. It also appears that alpha
lipoic acid may have a lesser effect on pain as compared to
pregabalin but its anti-inflammatory and antioxidant ac-
tions may contribute significantly to an all-round im-
provement in the symptoms of DN. To sum up the results
of VAS and DNS, it can be stated that the reduction in
pain (as per VAS) is superior with pregabalin (as com-
pared to alpha-lipoic acid and carbamazepine). However,
the reduction in symptom score (as per DNS) is same with
pregabalin and alpha lipoic acid. Carbamazepine shows a
poor rate and extent of improvement.
Another special test conducted during this study was
diabetic neuropathy examination (DNE) score. This is a
sensitive and well-recognized scoring system that is fast
and easy to perform in clinical practice. Its predictive
value is high both for screening and prognosis of diabeticneuropathy [11]. It consists of examination of various sen-
sations, reflexes and muscle strength in lower limbs. Total
score greater than 3 (out of 16) is considered as presence
of diabetic peripheral neuropathy. The mean DNE score
in all three groups in our study was nearly 8 at baseline.
The number of patients with <3 score (no DN) showed
statistically significant increase only in the pregabalin
group. This indicates the superiority of pregabalin over
other drugs. The reason for better improvement with
pregabalin may be due to its multiple actions as antiepi-
leptic and anxiolytic agent in addition to its analgesic
action. An additional central nervous system effect is
also likely which may be beneficial in improving the
parameters of DNE. Carbamazepine also has central ac-
tions but it showed a lesser improvement compared to
pregabalin. It may be noted here that carbamazepine
acts through sodium channels while pregabalin acts pre-
dominantly on calcium channels. The action on calcium
channel modulates the release of various neurotrans-
mitters in CNS [24] and this may result in a better effect
of pregabalin. However, despite the lack of a central ac-
tion alpha lipoic acid also showed a beneficial effect
which was better than carbamazepine which may be
due to its additional anti-inflammatory and antioxidant
action [25,26]. It is summed up that the improvement in
sensations, reflexes and muscle strength in patients of
DN was observed to be best with pregabalin (as per
DNE score). The unique effect of pregabalin on calcium
channel and thus on neurotransmitter release may be
responsible for this.
We also conducted the tests on nerve conduction vel-
ocity in patients of DN in this study. Nerve conduction
velocity (NCV) is the most sensitive and specific method
for detection of DN. The use of NCV is recommended
for early diagnosis as well as follow-up in DN [27]. Com-
paring the improvement in NCV at the end of study
showed no significant change in all three groups. Perhaps
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the reason for this. However, failure of improvement in
NCV by pregabalin has been reported by others also [28].
A study conducted in India has also described the similar
findings for carbamazepine [29]. On the other hand, a
meta-analysis conducted for alpha-lipoic acid has showed
significant improvement in NCV [30]. In this analysis a
higher dose of alpha-lipoic acid (300–600 mg, iv) was
reported to show the benefit while a lower dose 200 mg
orally has only been used in our study.
A strong correlation between improvement in glycemic
control and diabetic neuropathy has been reported in vari-
ous trials [18]. In present study, a significant (p < 0.05) im-
provement in various tests of diabetic neuropathy (VAS,
DNS and DNE) and glycemic control (FBS) was observed
separately with all three treatments. It gives an impression
that the improvement in DN may have been due to the
improved glycemic control with anti-diabetic drug ther-
apy. On further analysis, however, it was observed that a
significant correlation between FBS and the parameters of
DN did not exist in any of the groups. A small exception
was the correlation between FBS and improved VAS score
in patient treated with carbamazepine. It is therefore
opined that the improvement in DN in any of the groups
was not due to a better glycemic control but it rather ap-
pears to be due to the specific treatment (carbamazepine,
pregabalin and alpha lipoic acid) received by the patients.
It is also concluded that the medication received by the
patients in our study was very well tolerated as very few
adverse drug reactions of mild variety were reported
during this period.Conclusion
Results of this study suggest that treatment with prega-
balin is associated with faster and better improvement in
diabetic neuropathy. Effectiveness of alpha lipoic acid
appears to be equivalent to pregabalin. However, carba-
mazepine appeared to be inferior to the other two drugs.
Use of pregabalin as first line therapy in diabetic neur-
opathy is, therefore, justified and recommended.
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